Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy

Circulation Research

Volumn 86, Issue 7, 2000, Pages 737-744

  Tyska, M J ^a,d   Hayes, E ^a   Giewat, M ^b   Seidman, C E ^c   Seidman, J G ^b   Warshaw, D M ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

Cardiac myosin; Familial hypertrophic cardiomyopathy; Molecular motor; R403Q mouse model laser trap

Indexed keywords

ACTIN; ADENOSINE TRIPHOSPHATASE; MOLECULAR MOTOR; MYOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FAMILIAL DISEASE; HYPERTROPHIC CARDIOMYOPATHY; MISSENSE MUTATION; MOUSE; MUSCLE FORCE; MUSCLE ISOMETRIC CONTRACTION; NEWBORN; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ISOLATION;

EID: 0034646743     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.86.7.737     Document Type: Article

References (44)

1. Maron BJ. Hypertrophic cardiomyopathy. Lancet. 1997;350:127-133.
2. Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: pathology and pathogenesis. Histopathology. 1995;26:493-500.
3. Solomon SD, Wolff S, Watkins H, Ridker PM, Corne P, McKenna WJ, Seidman CE, Lee RT. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol. 1993;22:498-505.
4. Watkins H, MacRae C, Thierfelder L, Chou YH, Frenneaux M, McKenna W, Seidman JG, Seidman CE. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet. 1993;3:333-337.
5. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999-1006.
6. Watkins H. Multiple disease genes cause hypertrophic cardiomyopathy. Br Heart J. 1994;72:S4-S9.
7. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res. 1998;83:580-593.
8. Vikstrom KL, Leinwand LA. Contractile protein mutations and heart disease. Curr Opin Cell Biol. 1996;8:97-105.
9. Marian AJ, Kelly D, Mares AJ, Fitzgibbons J, Caira T, Qun T, Hill R, Perryman MB, Roberts R. A missense mutation in the beta myosin heavy chain gene is a predictor of premature sudden death in patients with hypertrophic cardiomyopathy. J Sports Med Phys Fitness. 1994; 34:1-10.
10. Rayment I, Holden HM, Sellers JR, Fananapazir L, Epstein ND. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A. 1995;92:3864-3868.
11. Epstein ND, Cohn GM, Cyran F, Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene: a 908Leu-Val mutation and a 403Arg-Gln mutation. Circulation. 1992;86:345-352.
12. Cuda G, Fananapazir L, Zhu WS, Sellers JR, Epstein ND. Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest. 1993;91:2861-2865.
13. Lankford EB, Epstein ND, Fananapazir L, Sweeney HL. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest. 1995;95:1409-1414.
14. Becker KD, Gottshall KR, Hickey R, Perriard JC, Chien KR. Point mutations in human beta cardiac myosin heavy chain have differential effects on sarcomeric structure and assembly: an ATP binding site change disrupts both thick and thin filaments, whereas hypertrophic cardiomyopathy mutations display normal assembly. J Cell Biol. 1997;137: 131-140.
15. Vybiral T, Deitiker PR, Roberts R, Epstein HF. Accumulation and assembly of myosin in hypertrophic cardiomyopathy with the 403 Arg to Gln beta-myosin heavy chain mutation. Circ Res. 1992;71: 1404-1409.
16. Cuda G, Fananapazir L, Epstein ND, Sellers JR. The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil. 1997;18:275-283.
17. Sweeney HL, Straceski AJ, Leinwand LA, Tikunov BA, Faust L. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J Biol Chem. 1994;269:1603-1605.
18. Fujita H, Sugiura S, Momomura S, Sugi H, Sutoh K. Functional characterization of Dictyostelium discoideum mutant myosins equivalent to human familial hypertrophie cardiomyopathy. Adv Exp Med Biol. 1998; 453:131-137.
19. Roopnarine O, Leinwand LA. Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy. Biophys J. 1998;75: 3023-3030.
20. Sata M, Ikebe M. Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy: implication for the clinical outcome. J Clin Invest. 1996; 98:2866-2873.
21. Geisterfer-Lowrance AA, Christe M, Conner DA, Ingwall JS, Schoen FJ, Seidman CE, Seidman JG. A mouse model of familial hypertrophic cardiomyopathy. Science. 1996;272:731-734.
22. Georgakopoulos D, Christe ME, Giewat M, Seidman CM, Seidman JG, Kass DA. The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation. Nat Med. 1999;5:327-330.
23. Hasty P, Ramirez-Solis R, Krumlauf R, Bradley A. Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells. Nature. 1991;350:243-246. (Correction. 1991;353:94).
24. Valancius V, Smithies O. Testing an "in-out" targeting procedure for making subtle genomic modifications in mouse embryonic stem cells. Mol Cell Biol. 1991;11:1402-1408.
25. Nguyen TT, Hayes E, Mulieri LA, Leavitt BJ, ter Keurs HE, Alpert NR, Warshaw DM. Maximal actomyosin ATPase activity and in vitro myosin motility are unaltered in human mitral regurgitation heart failure. Circ Res. 1996;79:222-226.
26. Warshaw DM, Desrosiers JM, Work SS, Trybus KM. Smooth muscle myosin cross-bridge interactions modulate actin filament sliding velocity in vitro. J Cell Biol. 1990;111:453-463.
27. Lanzetta PA, Alvarez LJ, Reinach PS, Candia OA. An improved assay for nanomole amounts of inorganic phosphate. Anal Biochem. 1979;100: 95-97.
28. Warshaw DM, Desrosiers JM, Work SS, Trybus KM. Mechanical interaction of smooth muscle crossbridges modulates actin filament velocity in vitro. Prog Clin Biol Res. 1990;327:815-826.
29. Finer JT, Simmons RM, Spudich JA. Single myosin molecule mechanics: piconewton forces and nanometre steps. Nature. 1994;368:113-119.
30. Guilford WH, Dupuis DE, Kennedy G, Wu J, Patlak JB, Warshaw DM. Smooth muscle and skeletal muscle myosins produce similar unitary forces and displacements in the laser trap. Biophys J. 1997;72: 1006-1021.
31. Dupuis DE, Guilford WH, Wu J, Warshaw DM. Actin filament mechanics in the laser trap. J Muscle Res Cell Motil. 1997;18:17-30.
32. Harris DE, Work SS, Wright RK, Alpert NR, Warshaw DM. Smooth, cardiac and skeletal muscle myosin force and motion generation assessed by cross-bridge mechanical interactions in vitro. J Muscle Res Cell Motil. 1994;15:11-19.
33. Blanchard E, Seidman C, Seidman JG, LeWinter M, Maughan D. Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circ Res. 1999;84:475-483.
34. Yamashita H, Lowey S, Trybus KM. Functional consequences of myosin heavy chain mutations implicated in familial hypertrophic cardiomyopathy. Biophys J. 1997;72:A339.
35. McNally EM, Kraft R, Bravo-Zehnder M, Taylor DA, Leinwand LA. Full-length rat alpha and beta cardiac myosin heavy chain sequences: comparisons suggest a molecular basis for functional differences. J Mol Biol. 1989;210:665-671.
36. Palmiter KA, Tyska MJ, Dupuis DE, Alpert N, Warshaw DM. Kinetic differences determined at the single molecule level account for the functional diversity of rabbit cardiac myosin isoforms. J Physiol (Lond). 1999;519:669-678.
37. Palmiter KA, Alpert NR, Fananapazir L, Warshaw DM. Single cardiac myosin molecules from familial hypertrophic cardiomyopathy patients exhibit enhanced mechanical performance in the laser trap assay. Circulation. 1999;100(suppl I):I-193-I-194. Abstract.
38. Lauzon AM, Tyska MJ, Rovner AS, Freyzon Y, Warshaw DM, Trybus KM. A 7-amino-acid insert in the heavy chain nucleotide binding loop alters the kinetics of smooth muscle myosin in the laser trap. J Muscle Res Cell Motil. 1998;19:825-837.
39. Siemankowski RF, White HD. Kinetics of the interaction between actin, ADP, and cardiac myosin-S1. J Biol Chem. 1984;259:5045-5053.
40. Siemankowski Rf, Wiseman MO, White HD. ADP dissociation from actomyosin subfragment 1 is sufficiently slow to limit the unloaded shortening velocity in vertebrate muscle. Proc Natl Acad Sci U S A. 1985;82:658-662.
41. Marston SB, Taylor EW. Comparison of the myosin and actomyosin ATPase mechanisms of the four types of vertebrate muscles. J Mol Biol. 1980;139:573-600.
42. Tyska MJ, Dupuis DE, Guilford WH, Patlak JB, Waller GS, Trybus KM, Warshaw DM, Lowey S. Two heads of myosin are better than one for generating force and motion. Proc Natl Acad Sci USA. 1999;96: 4402-4407.
43. Spindler M, Saupe KW, Christe ME, Sweeney HL, Seidman CE, Seidman JG, Ingwall JS. Diastolic dysfunction and altered energetics in the alpha-MHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest. 1998;101:1775-1783.
44. Kammermeier H. High energy phosphate of the myocardium: concentration versus free energy change. Basic Res Cardiol. 1987;82(suppl 2):31-6-31-36.